Back to top
more

Entera Bio (ENTX)

(Delayed Data from NSDQ)

$1.98 USD

1.98
118,867

-0.02 (-1.00%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.97 -0.01 (-0.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw Entera Bio Ltd. (ENTX) settling at $1.98, representing a -1% change from its previous close.

Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today

In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.

Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 33.33% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know

Entera Bio Ltd. (ENTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?

In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.

Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know

Entera Bio Ltd. (ENTX) closed the most recent trading day at $0.91, moving +1.11% from the previous trading session.

Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know

Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.

Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know

Entera Bio Ltd. (ENTX) closed at $0.90 in the latest trading session, marking a -1% move from the prior day.

Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.

Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know

In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.88, marking a +1.87% move from the previous day.

New Strong Buy Stocks for December 29th

SPNS, CRS, DHT, DCBO and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on December 29, 2022.

New Strong Buy Stocks for November 21st

AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.

Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD Drug

The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.

4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why

4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

New Strong Buy Stocks for November 16th

ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 19th

ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.